Nov 20 (Reuters) – Drug developer Savara said on Friday the US FDA would not meet its November 22 deadline to decide whether to approve the company’s treatment for a rare lung disease, dealing a setback to the biotech firm. Shares of the company were down 16% in premarket trading. • The US Food and […]
Health
FDA to miss deadline on Savara’s rare lung disease drug approval
Audio By Carbonatix
Nov 20 (Reuters) – Drug developer Savara said on Friday the US FDA would not meet its November 22 deadline to decide whether to approve the company’s treatment for a rare lung disease, dealing a setback to the biotech firm.
Shares of the company were down 16% in premarket trading.
• The US Food and Drug Administration did not provide a new date for a decision, Savara said, adding that its application for approval remains under review
• The company is seeking approval of its experimental drug, molgramostim, for autoimmune pulmonary alveolar proteinosis (PAP), a rare condition in which material builds up in the lungs, making it harder for patients to breathe
• Molgramostim is designed to help immune cells in the lungs clear that material. The drug is delivered through a nebulizer
• The FDA had previously extended its review by three months to assess additional information submitted by Savara. At the time, the company said the regulator had not identified any safety, effectiveness or manufacturing concerns
• There are currently no FDA-approved treatments for autoimmune PAP. Available care includes whole-lung lavage, an invasive procedure performed under general anesthesia in which the lungs are repeatedly washed to remove the buildup
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Diti Pujara)

